SCHEMBL24549099

SCHEMBL24549099

CC(=O)N1CCC(c2ccc3[nH]c(Nc4cc(Cl)c5cc[nH]c5c4)nc3c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKAB2 O43741 3/20 0.43
▸ PRKAG1 P54619 3/20 0.43
▸ PRKAA2 P54646 3/20 0.43
▸ PRKAA1 Q13131 3/20 0.43
▸ PRKAG3 Q9UGI9 3/20 0.43
▸ PRKAG2 Q9UGJ0 3/20 0.43
▸ PRKAB1 Q9Y478 3/20 0.43
▸ TLR7 Q9NYK1 6/20 0.42
▸ TLR8 Q9NR97 5/20 0.42
▸ TLR9 Q9NR96 3/20 0.42
▸ QDPR P09417 2/20 0.39
▸ HAT1 O14929 1/20 0.38
▸ EP300 Q09472 1/20 0.38
▸ BTK Q06187 2/20 0.37
▸ ZAP70 P43403 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ TYK2 P29597 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ ENPP2 Q13822 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29653785 1.00 PRKAB2 (0.43) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24549268 0.91 HTR2B (0.41) TLR7TLR8TLR9BTKFASN
SCHEMBL24549212 0.89 JAK1 (0.42) TLR7TLR8TLR9JAK2JAK1
SCHEMBL29653689 0.89 JAK1 (0.42) TLR7TLR8TLR9JAK2JAK1
SCHEMBL24549232 0.88 KCNH2 (0.44) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24549228 0.87 SYK (0.38) BTKPOLB
SCHEMBL24549269 0.86 BTK (0.39) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24549239 0.84 BTK (0.42) BTK
SCHEMBL29132145 0.83 BTK (0.37) TLR7TLR8TLR9BTK
SCHEMBL24549235 0.83 SYK (0.38) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051970-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2024-02-15 — — US disclosed
CN-117321048-A Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2023-12-29 — — CN disclosed
WO-2022133098-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051970-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 PRKAB2 158/4885PRKAG1 57/4885PRKAA2 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback